ReviewEuropean journal of human genetics : EJHG2018
Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature.
Review in European journal of human genetics : EJHG, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Combination therapy with mycophenolate mofetil, nintedanib, and tocilizumab in a patient with progressive systemic sclerosis-associated interstitial lung disease : A case report and a literature review.Zeitschrift fur Rheumatologie · 2026Review
- Systemic Sclerosis with Interstitial Lung Disease: Identification of Novel Immunogenetic Markers and Ethnic Specificity in Kazakh Patients.Epidemiologia (Basel, Switzerland) · 2025Article
- Article
- Respiratory tract lining fluid copper content contributes to pulmonary oxidative stress in patients with systemic sclerosis.Wellcome open research · 2024Article
- [Characteristics of patients with systemic sclerosis who develop interstitial lung disease].Revista medica del Instituto Mexicano del Seguro Social · 2023Observational
- Biomarkers in Systemic Sclerosis: An Overview.Current issues in molecular biology · 2023Review
- Pulmonary hypertension in systemic sclerosis with usual interstitial pneumonia.Internal and emergency medicine · 2023Article
- Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis.Journal of inflammation research · 2023Review
- Exome sequencing link mutation inFrontiers in oncology · 2022Article
- Management of Connective Tissue Disease-related Interstitial Lung Disease.Current pulmonology reports · 2022Review
- Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations.Frontiers in immunology · 2021Review
- The Downregulation of PTGS2 Mediated by ncRNAs is Tightly Correlated with Systemic Sclerosis-Interstitial Lung Disease.Frontiers in genetics · 2021Article
- Definition of Naturally Processed Peptides Reveals Convergent Presentation of Autoantigenic Topoisomerase I Epitopes in Scleroderma.Arthritis & rheumatology (Hoboken, N.J.) · 2020Observational
- Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2020Article
- Pathogenesis of systemic sclerosis associated interstitial lung disease.Journal of scleroderma and related disorders · 2020Article
- Immunopathogenesis of Juvenile Systemic Sclerosis.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The interplay between genetic and environmental factors is likely involved in the pathogenesis of systemic sclerosis (SSc). Interstitial lung disease associated in the context of SSc (SSc-ILD) is associated with significant morbidity, and is the leading cause of death in SSc. The spectrum of SSc-ILD severity is wide, ranging from patients with only limited and inherently stable pulmonary involvement, to those with extensive and progressive pulmonary fibrosis. In order to provide accurate prognostic information for patients, and to initiate appropriate monitoring and treatment regimens, the ability to identify patients at risk of developing severe ILD early in the disease course is crucial. Identification of genetic variants involved in disease pathogenesis can not only potentially provide diagnostic/prognostic markers, but can also highlight dysregulated molecular pathways for therapeutic targeting. A number of genetic associations have been established for susceptibility to SSc, but far fewer studies have investigated genetic susceptibility to SSc-ILD specifically. In this review we present a summary of the studies assessing genetic associations with SSc-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.